<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02695160</url>
  </required_header>
  <id_info>
    <org_study_id>SB-FIX-1501</org_study_id>
    <nct_id>NCT02695160</nct_id>
  </id_info>
  <brief_title>Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B</brief_title>
  <official_title>A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sangamo Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sangamo Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability and effect on FIX antigen&#xD;
      and activity levels of ascending doses of SB-FIX. SB-FIX is an intravenously delivered Zinc&#xD;
      Finger Nuclease (ZFN) Therapeutic for genome editing. It inserts a correct copy of the Factor&#xD;
      9 gene into the albumin locus in hepatocytes with the goal of lifelong therapeutic production&#xD;
      of the Factor IX clotting factor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to provide long term expression of Factor IX in subjects with&#xD;
      severe hemophilia B. SB-FIX is a therapeutic for ZFN-mediated genome editing which will be&#xD;
      delivered by adeno-associated virus (AAV)-derived vectors. SB-FIX is intended to function by&#xD;
      placement of a corrective copy of the Factor IX transgene into the genome of the subject's&#xD;
      own hepatocytes, under the control of the highly expressed endogenous albumin locus, and is&#xD;
      expected to provide permanent, liver-specific expression of Factor IX for the lifetime of a&#xD;
      hemophilia B subject.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">November 15, 2016</start_date>
  <completion_date type="Actual">April 19, 2021</completion_date>
  <primary_completion_date type="Actual">April 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related Adverse Events in subjects who received SB-FIX as assessed by Common Terminology Criteria for Adverse Events (CTCAE)</measure>
    <time_frame>Up to 36 months after the SB-FIX infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FIX antigen and activity levels</measure>
    <time_frame>up to 36 months after the SB-FIX infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and shedding of AAV2/6 vector DNA by PCR in plasma, saliva, urine, stool and semen</measure>
    <time_frame>Follow up until 2 consecutive measurements are negative of AAV</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB-FIX: Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB-FIX: Medium Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB-FIX: High Dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB-FIX</intervention_name>
    <description>Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male &gt;18 years of age&#xD;
&#xD;
          -  Severe hemophilia B (native circulating FIX activity &lt;1%, with or without cross&#xD;
             reactive material)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of neutralizing antibodies&#xD;
&#xD;
          -  History of hypersensitivity response or an allergic reaction to FIX or FIX products&#xD;
&#xD;
          -  Currently receiving long acting FIX replacement therapy&#xD;
&#xD;
          -  FIX mutations known to be associated with FIX inhibitors&#xD;
&#xD;
          -  Polymorphisms in the ZFN target region&#xD;
&#xD;
          -  Presence of any liver mass on MRI, or elevated alpha-fetoprotein (AFP)&#xD;
&#xD;
          -  Any contraindication to the use of corticosteroids for immunosuppression&#xD;
&#xD;
          -  Currently receiving antiviral therapy for hepatitis B or C or with history or active&#xD;
             hepatitis B or hepatitis C or HIV-1 or HIV1/2 antibody positive.&#xD;
&#xD;
          -  Chronic anemia, leukopenia, or thrombocytopenia&#xD;
&#xD;
          -  Past medical history of active tuberculosis or significant fungal disease&#xD;
&#xD;
          -  Symptomatic cardiovascular disease as a co-morbid condition&#xD;
&#xD;
          -  Markers of hepatic inflammation or overt or occult cirrhosis&#xD;
&#xD;
          -  History of chronic renal disease or creatinine â‰¥ 1.5 mg/dL&#xD;
&#xD;
          -  Systemic (iv or oral) immunomodulatory agent or steroid use (topical treatment is&#xD;
             allowed)&#xD;
&#xD;
          -  History of chronic infection or other chronic disorder considered an unacceptable risk&#xD;
&#xD;
          -  History of malignancy except for treated basal cell or squamous cell carcinoma&#xD;
&#xD;
          -  History of alcohol or substance abuse&#xD;
&#xD;
          -  Previously received gene therapy product&#xD;
&#xD;
          -  Participation in prior investigational drug or medical device study within the&#xD;
             previous 3 months&#xD;
&#xD;
          -  History of therapeutic non-adherence&#xD;
&#xD;
          -  Any other reason that, in the opinion of the Investigator or Medical Monitor, would&#xD;
             render the subject unsuitable for participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Sangamo Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 24, 2016</study_first_submitted>
  <study_first_submitted_qc>February 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2016</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

